Renko chart makes identification of key easier. Moreover one easily sees that they tightly fit with Fibo levels. We are currently in a downtrend towards the main year support which was tested in spring and in fall. An investor may be interested to enter at the 97 area, this would be a fair price for a whose average target price is 128.3 (tipranks.com) and rated as "strong buy". I don't own this currently, I'm long CELG but I consider buying GILD someday.
It took about 3 months to get at the 121 levels from March to June 2015. The market in biotechs is still shy due to presidential threats, and Gilead was one of the target of politicals due to its high prices, the upward pace will be slower I guess. I have access to details of the UBS analysis regarding GILD. Last report is from 17th december 2015 and their 12-month target price is 138$, they mentioned Filgotinib as one of the catalysts. In all cases, by doing a simple linear interpolation, it makes about 3$ per month, so it could reach it in 9 months or so near the US elections. Have a look at Seeking Alpha articles regarding GILD, there are lot of analysts giving some insights about the future trend of this stock (http://seekingalpha.com/symbol/GILD).